Biography
Ken Drazan, MD, is the Chairman, CEO, and Co-Founder of ArsenalBio, a pioneering company in the field of cell therapy and gene editing. Prior to his role at ArsenalBio, Dr. Drazan served as President and Chief Business Officer of GRAIL, a company focused on early cancer detection which was acquired by Illumina. He also founded and was a Board Director at Verb Surgical, which was later acquired by Johnson Johnson. Additionally, Dr. Drazan co-founded Bertram Capital, a private equity firm managing $1.9 billion in assets. He earned his medical degree from Yale University. Throughout his career, Dr. Drazan has been instrumental in advancing technologies that leverage AI and high-performance computing in precision medicine, significantly impacting the fields of gene editing and cell therapy.